No pharmaceutical opinion available for this interaction.
Elvitegravir / Cobicistat can inhibit the metabolism (CYP 3A4) and increase the plasma concentration of Amlodipine.
Elvitegravir 3A4 and then UGT1A1/3; Cobicistat 3A4 (major) and 2D6 (minor)
Elvitegravir : 2C9 (moderate)
Cobicistat : 3A4 and 2D6 (potent), P-gp, MATE 1, BCRP, OATP1B1 and OATP1B3
3A4 (major) inactive metabolites
1A2 (moderate) > 2A6, 2B6, 2C8, 2C9, 3A4, et 2D6 (weak)
Increased risk of adverse effects.
Use this combination with caution.
Start treatment with lower dose possible.
Reduce the dose of the CCB if judged necessary and gradually increase according to clinical response and tolerance.
In patients already being treated with this combination and tolerating it, if deemed appropriate, keep actual treatment and exercise close monitoring of adverse effects.
Or choose an alternative.
Diuretics, ACE inhibitors and some ARBs (if no contranindications).
Adverse effects associated with calcium channel blockers : headache, peripheral edema, gastrointestinal effects, fatigue, hypotension, palpitations, tachycardia or bradycardia (diltiazem and verapamil), dizziness, nervousness, vertigo and drowsiness.
When possible, monitor the effects on blood pressure, heart rate and ECG.
Advise patient to consult quickly if lower limb edema, sudden weight gain, difficulty breathing, chest pain or tightness, or hypotension (dizziness, orthostatic effects).
Ref #2772 : The monograph recommends to advise patients to rapidly consult if they have edema of the lower limbs, sudden weight gain, difficulty breathing, chest pain or hypotension (dizziness, orthostatic effects, etc).
Ref #2407: In one study, patients who received indinavir 800 mg + ritonavir 100 mg BID with amlodipine 5 mg QD had an increase in amlodipine AUC of approximately 90%. Other patients received indinavir 800 mg + ritonavir 100 mg BID with diltiazem 120 mg QD and a 26.5% increase in diltiazem AUC was observed. 13 patients in the study, two subjects had an increase in diltiazem AUC of 4 times the normal. By cons, no serious adverse effects on the cardiovascular system was observed.
The searchers therefore recommend, if co-administration is indicated, to initiate treatment with amlodipine with low doses increasing doses with caution according to clinical response and the occurrence of adverse effects.